ArticleBrain research2014
Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease.
Article in Brain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- New molecular markers to differentiate carbon dioxide intoxication from asphyxia due to oxygen deficiency.Forensic science, medicine, and pathology · 2025Article
- The Diagnostic Value of Cerebrospinal Fluid Neurogranin in Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Molecular Characterization of Neurogranin (NRGN) Gene from Red‑Bellied Pacu (Piaractus brachypomus).Molecular neurobiology · 2024Article
- Altered perivascular spaces in subcortical white matter in Parkinson's disease patients with levodopa-induced dyskinesia.NPJ Parkinson's disease · 2024Article
- Neurogranin-like immunoreactivity in the zebrafish brain during development.Brain structure & function · 2022Article
- Distribution of neurogranin-like immunoreactivity in the brain and sensory organs of the adult zebrafish.The Journal of comparative neurology · 2022Article
- Fluid markers of synapse degeneration in synucleinopathies.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.Biomolecules · 2021Article
- LINC00641/miR-4262/NRGN axis confines cell proliferation in glioma.Cancer biology & therapy · 2020Article
- Neurogranin: A Potential Biomarker of Neurological and Mental Diseases.Frontiers in aging neuroscience · 2020Review
- Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury.Journal of neuroinflammation · 2018Article
- Disruption of Inferior Longitudinal Fasciculus Microstructure in Parkinson's Disease: A Systematic Review of Diffusion Tensor Imaging Studies.Frontiers in neurology · 2018Review
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.JAMA neurology · 2015Article
- Adult Astrogenesis and the Etiology of Cortical Neurodegeneration.Journal of experimental neuroscience · 2015Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Neurogranin is a calmodulin binding protein that has been implicated in learning and memory, long-term potentiation and synaptic plasticity. Neurons expressing neurogranin in the cortex degenerate in late stages of Parkinson's disease with widespread α-synuclein pathology. While analyzing neurogranin gene expression levels through rtPCR in brains of mouse models overexpressing human α-synuclein, we found levels were elevated 2.5 times when compared to nontransgenic animals. Immunohistochemistry in the cortex revealed colocalization between α-synuclein and neurogranin in mouse transgenics when compared to control mice. Coimmunoprecipitation studies in the superior temporal cortex in humans confirmed interaction between α-synuclein and neurogranin, and decreased interaction between α-synuclein and neurogranin was noticed in patients diagnosed with Parkinson's disease when compared to normal control brains. Additionally, phosphorylated neurogranin levels were also decreased in the human superior temporal cortex in patients diagnosed with Parkinson's disease and patients diagnosed with dementia with Lewy bodies. Here, we show for the first time that neurogranin binds to α-synuclein in the human cortex, and this interaction decreases in Parkinson's disease along with the phosphorylation of neurogranin, a molecular process thought to be involved in learning and memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.